Skip to main content

Endothelin Receptor Antagonists

Promising New Agents in the Management of Cardiovascular Disorders

Abstract

Since its discovery in 1988, endothelin (ET) has been widely implicated in the pathophysiology of cardiovascular disease. ET antagonists have favourable effects in experimental models of these conditions and have proved useful in elucidating the role of the ET system. Orally acting ET antagonists appear very promising in clinical trials, particularly in patients with chronic heart failure and hypertension, but more information on the roles of the ET receptor subtypes in health and disease is required so that an informed choice can be made between the use of endothelin-A (ET-A) receptor-selective and nonselective receptor antagonists.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332 (6163): 411–5

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86 (8): 2863–7

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Arinami T, Ishikawa M, Inoue A, et al. Chromosomal assignments of the human endothelin family genes: The endothelin- 1 gene (EDN1) to 6p23–p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2–q13.3. Am J Hum Genet 1991; 48 (5): 990–6

    PubMed  CAS  Google Scholar 

  4. 4.

    Eid H, de Bold ML, Chen JH, et al. Epicardial mesothelial cells synthesize and release endothelin. J Cardiovasc Pharmacol 1994; 24 (5): 715–20

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Kohan DE. Endothelins in the kidney: physiology and pathophysiology. Am J Kidney Dis 1993; 22 (4): 493–510

    PubMed  CAS  Google Scholar 

  6. 6.

    Rossi GP, Colona S, Pavan E, et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 1999; 99 (9): 1147–55

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Brown MA, Smith PL. Endothelin: a potent stimulator of intestinal ion secretion in vitro. Regul Pept 1991; 36 (1): 1–19

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Garvin J, Sanders K. Endothelin inhibits fluid and bicarbonate transport in part by reducing Na+/K+ ATPase activity in the rat proximal straight tubule. J Am Soc Nephrol 1991; 2 (5): 976–82

    PubMed  CAS  Google Scholar 

  9. 9.

    Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16 (8): 1081–98

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348 (6303): 730–2

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990; 348 (6303): 732–5

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a nonisopeptide- selective human endothelin receptor. Biochem Biophys Res Commun 1991; 178 (1): 248–255

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Karet F, Kuc R, Davenport A. Novel ligands BQ 123 and BQ 3020 characterise endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 1993; 44 (1): 36–42

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996; 72 (2): 109–48

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Douglas SA. Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci 1997; 18 (11): 408–12

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Fukami T, Niiyami K, Amano Y, et al. Cyclic pentapeptide endothelin A receptor antagonists with attenuated in vivo clearance. Chem Pharm Bull 1996; 44 (3): 609–14

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Webb ML, Meek TD. Inhibitors of endothelin. Med Res Rev 1997; 17 (1): 17–67

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Liu G, Henry Jr KJ, Szczepankiewicz BG, et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists: 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonists (A-216546). J Med Chem 1998; 41 (17): 3261–75

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Wu C, Chan MF, Stavros F, et al. Discovery of TBC-11251, a potent, long-acting, orally active endothelin receptor-Aselective antagonist. J Med Chem 1997; 40 (11): 1690–7

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Hoshino T, Yamauchi R, Kikkawa K, et al. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther 1998; 286 (2): 643–9

    PubMed  CAS  Google Scholar 

  21. 21.

    Sorensen SS, Madsen JK, Pedersen EB. Systemic and renal effects of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 1994; 266 (3 Pt 2): F411–8

    PubMed  CAS  Google Scholar 

  22. 22.

    Cirino M, Martin E, Yano M, et al. Cardiovascular and renal actions of the endothelin (B) receptor in pigs. J Cardiovasc Pharmacol 1997; 29 (6): 704–12

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Moravec CS, Reynolds EE, Stewart RW, et al. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun 1989; 159 (1): 14–8

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Pieske B, Beyermann B, Breu V, et al. Functional effects of endothelin regulation of endothelin receptors in isolated human nonfailing and failingmyocardium. Circulation 1999; 99 (14): 1082–9

    Article  Google Scholar 

  25. 25.

    Beyer ME, Slesak G, Hovelborn T, et al. Inotropic effects of endothelin-1. Interaction withmolsidomine and with BQ 610. Hypertension 1999; 33 (1): 145–52

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Rabelink TJ, Kaasjager KA, Boer P, et al. Effects of endothelin- 1 on renal function in humans: Implications for physiology and pathophysiology. Kidney Int 1994; 46 (2): 376–81

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Kruger D, Sheikzadeh A, Giannitsis E, et al. Cardiac release and kinetics of endothelin after severe short-lasting myocardial ischaemia. J Am Coll Cardiol 1997; 30 (4): 942–6

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Yasuda M, Kohno M, Tahara A, et al. Circulating immunoreactive endothelin in ischaemic heart disease. Am Heart J 1990; 119 (4): 801–6

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Toyo-oka T, Aizawa T, Suzuki N, et al. Increased plasma level of endothelin-1 and coronary spasminduction in patientswith vasospastic angina pectoris. Circulation 1991; 83 (2): 476–83

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Ray SG, McMurray JJ, Morton JJ, et al. Circulating endothelin in acute ischaemic syndromes. Br Heart J 1992; 67 (5): 383–6

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Wieczorek I, Haynes WG, Webb DJ, et al. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994; 72 (5): 436–41

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89 (4): 1573–9

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Richards AM, Webb DJ, Yandle TG, et al. Comparison of amino terminal pro-brain natriuretic peptide and big endothelin-1 as prognostic indicators after myocardial infarction [abstract]. J Am Coll Cardiol 1999; 33 (2 Suppl. A): 194A

    Google Scholar 

  34. 34.

    Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89 (3): 1203–8

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Awane-Igata Y, Ikeda S, Watanabe T. Inhibitory effects of TAK- 044 on endothelin induced vasoconstriction in various canine arteries and porcine coronary arteries: a comparison with selective ETA and ETB receptor antagonists. Br J Pharmacol 1997; 120 (3): 516–22

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98 (21): 2235–40

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Grover GJ, Dzonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27 (9): 1613–8

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Watanabe T, Awane Y, Ikeda S, et al. Pharmacology of a nonselective ETA and ETB receptor antagonist, TAK 044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995; 114 (5): 949–54

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325 (14): 997–1001

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Zeiher AM, Gobel H, Schachinger V, et al. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91 (4): 941–7

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Kowala MC, Rose PM, Stein PD, et al. Selective blockade of the endothelin subtype Areceptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995; 146 (4): 819–26

    PubMed  CAS  Google Scholar 

  42. 42.

    Barton M, Haudenschild CC, D’Uscio LV, et al. Endothelin ET(A) receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 95(24): 14367–72

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Best PJM, McKenna CJ, Hasdai D, et al. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolaemia. Circulation 1999; 99 (13): 1747–52

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Hirata Y, Takagi Y, Fukuda Y, et al. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78 (2–3): 225–8

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Weissberg PL, Witchell C, Davenport AP, et al. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis 1990; 85 (2–3): 257–62

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Wang X, Douglas SA, Louden C, et al. Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin- A and endothelin-B receptor mRNAs after angioplasty induced neointimal formation in the rat. Circ Res 1996; 78 (2): 322–8

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Douglas SA, Louden C, Vickery-Clark LM, et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel non-peptide endothelin receptor antagonist SB 209670. Circ Res 1994; 75 (1): 190–7

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Tahara A, Kohno M, Yanagai S, et al. Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty. Metabolism 1991; 40 (12): 1235–7

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Hasdai D, Holmes DRJ, Garratt KN, et al.Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997; 95 (2): 357–62

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Douglas SA, Vickery-Clarke LM, Louden C, et al. Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: a comparison of selective ETA receptor antagonism and dual ETA/ETB receptor antagonism using BQ-123 and SB 209670. J Cardiovasc Pharmacol 1995; 26 (3 Suppl.): S186–9

    Google Scholar 

  51. 51.

    Chandra S, Sarkar S, Elliott JD, et al. Application of magnetic resonance imaging for evaluation of the efficacy of SB 217242 in neointimal formation. J Cardiovasc Pharmacol 1998; 31 (1 Suppl.): S317–9

    Article  Google Scholar 

  52. 52.

    McKenna CJ, Burke SE, Opgenorth TJ, et al. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 1998; 97 (25): 2551–6

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Douglas SA, Nichols AJ, Feuerstein GZ, et al. SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog. J Cardiovasc Pharmacol 1998; 31 (1 Suppl.): S99–102

    Article  Google Scholar 

  54. 54.

    Raschack M, Juchelka F, Rozek-Schaefer G. The endothelin-A antagonist LU 135 252 suppresses ischaemic extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling. J Cardiovasc Pharmacol 1998; 31 (1 Suppl.): S145–8

    Article  Google Scholar 

  55. 55.

    Garjani A, Wainwright CL, Zeitlin I, et al. Effects of endothelin- 1 and the ET(A) receptor antagonist BQ-123, on ischaemic arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995; 25 (4): 634–42

    PubMed  Article  CAS  Google Scholar 

  56. 56.

    Kramer BK, Ittner ME, Beyer ME, et al. Circulatory and myocardial effects of endothelin. J Mol Med 1997; 75 (11–12): 886–90

    PubMed  CAS  Google Scholar 

  57. 57.

    Prasad MR. Endothelin stimulates degradation of phospholipids in isolated rat hearts. Biochem Biophys Res Commun 1991; 174 (2): 952–7

    PubMed  Article  CAS  Google Scholar 

  58. 58.

    Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384 (6607): 353–5

    PubMed  Article  CAS  Google Scholar 

  59. 59.

    Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in themaintenance of cardiac function in ratswith congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93 (6): 1214–22

    PubMed  Article  CAS  Google Scholar 

  60. 60.

    Wei CM, Clavell AL, Burnett JCJ. Atrial and pulmonary endothelin mRNA is increased in a canine model of chronic low cardiac output. Am J Physiol 1997; 273 (2–2): R838–44

    PubMed  CAS  Google Scholar 

  61. 61.

    Tonnessen T, Lunde PK, Giaid A, et al. Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin- 1 mRNA and endothelin peptide. Cardiovasc Res 1998; 39 (3): 633–43

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Iwanaga Y, Kihara Y, Hasegawa K, et al. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 1998; 98 (19): 2065–73

    PubMed  Article  CAS  Google Scholar 

  63. 63.

    Teerlink JR, Breu V, Sprecher U, et al. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 1994; 74 (1): 105–14

    PubMed  Article  CAS  Google Scholar 

  64. 64.

    Cannan CR, Burnett Jr JC, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 1996; 93 (4): 646–51

    PubMed  Article  CAS  Google Scholar 

  65. 65.

    Love MP, Haynes WG, Gray GA, et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996; 94 (9): 2131–7

    PubMed  Article  CAS  Google Scholar 

  66. 66.

    Kelso EJ, Geraghty RF, McDermott BJ, et al. Mechanical effects of ET-1 in cardiomyocytes isolated from normal and heartfailed rabbits. Mol Cell Biochem 1996; 157 (1–2): 149–55

    PubMed  CAS  Google Scholar 

  67. 67.

    Thomas PB, Liu EC, Webb ML, et al. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. AmJ Physiol 1996; 271 (6 Pt 2): H2629–37

    CAS  Google Scholar 

  68. 68.

    Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodelling. Circulation 1997; 96 (6): 1976–82

    PubMed  Article  CAS  Google Scholar 

  69. 69.

    Shen Y-T, Buie P, Moussa T, et al. Chronic therapy with L-753,037, an ETA/B receptor antagonist, in conscious dogs during development of heart failure [abstract]. Circulation 1998; 98 (17 Suppl. I): I–578

    Google Scholar 

  70. 70.

    Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin- 1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71(15): 1293–9

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89 (4): 1580–6

    PubMed  Article  CAS  Google Scholar 

  72. 72.

    Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin- 1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346 (8977): 732–6

    PubMed  Article  CAS  Google Scholar 

  73. 73.

    Sütsch G, Kiowski W, Yan X-W, et al. Short-term oral endothelinreceptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98 (1): 2262–8

    PubMed  Article  Google Scholar 

  74. 74.

    Packer M, Caso A, Charlton V, et al. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with Bosentan in chronic heart failure — results of theREACH-1 trial [abstract]. Circulation 1998; 98 (17 Suppl. I): I–3

    Google Scholar 

  75. 75.

    Cowburn PJ, Cleland JGF, McArthur JD, et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet 1998; 352 (9123): 201–2

    PubMed  Article  CAS  Google Scholar 

  76. 76.

    Cowburn PJ, Cleland JGF, McDonagh TA, et al. Adverse hemodynamic effects of a selective endothelin ETB receptor antagonist in patients with chronic heart failure: reversal with a selective endothelin ETA receptor antagonist. Circulation 1998; 98 (17 Suppl. I): I–718

    Google Scholar 

  77. 77.

    Givertz MM, Colucci WS, Gottlieb SS, et al. Acute ETA receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure [abstract]. Circulation 1998; 98 (17 Suppl. I): I–578

    Google Scholar 

  78. 78.

    Webb DJ, Monge JC, Rabelink TJ, et al. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998; 19 (1): 5–8

    PubMed  Article  Google Scholar 

  79. 79.

    Rakugi H, Tabuchi Y, Nakamaru M, et al. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem Int 1990; 21 (5): 867–72

    PubMed  CAS  Google Scholar 

  80. 80.

    Ferro CJ, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996; 51 (1): 12–27

    PubMed  Article  CAS  Google Scholar 

  81. 81.

    Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344 (8926): 852–4

    PubMed  Article  CAS  Google Scholar 

  82. 82.

    Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92 (3): 357–63

    PubMed  Article  CAS  Google Scholar 

  83. 83.

    Haynes WG, Strachan FE, Gray GA, et al. Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol 1995; 26 (3 Suppl.): S40–3

    Google Scholar 

  84. 84.

    Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97 (8): 752–6

    PubMed  Article  CAS  Google Scholar 

  85. 85.

    Haynes WG, Ferro CJ, O’Kane KPJ, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93 (10): 1860–70

    PubMed  Article  CAS  Google Scholar 

  86. 86.

    Strachan FE, Spratt JC, Wilkinson IB, et al. Systemic blockade of the endothelin-B receptor increases peripheral resistance in healthy men. Hypertension 1999; 33 (1 Pt 2): 581–5

    PubMed  Article  CAS  Google Scholar 

  87. 87.

    Spratt JC, Goddard J, Labinjoh C, et al. Systemic blockade of the ETA receptor decreases peripheral vascular resistance in healthy men [abstract]. Br J Clin Pharmacol 1999; 47: 575P

    Google Scholar 

  88. 88.

    Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens 1998; 16 (12II): 1891–5

    PubMed  Article  CAS  Google Scholar 

  89. 89.

    Goddard J, Webb DJ. Plasma endothelin concentrations in hypertension. J Cardiovasc Pharmacol 1999. In press

    Google Scholar 

  90. 90.

    Cardillo C, Kilcoyne CM, Quyyumi AA, et al. Selective defect in nitric oxide synthesis may explain the impaired endothelium- dependent vasodilation in patients with essential hypertension. Circulation 1998; 97 (9): 851–6

    PubMed  Article  CAS  Google Scholar 

  91. 91.

    Cardillo C, Kilcoyne CM, Cannon RO, et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999; 99 (1): 90–5

    PubMed  Article  CAS  Google Scholar 

  92. 92.

    Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33 (2): 753–8

    PubMed  Article  CAS  Google Scholar 

  93. 93.

    Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998; 338 (12): 784–90

    PubMed  Article  CAS  Google Scholar 

  94. 94.

    Barone FC, White RF, Elliot JD, et al. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischaemic brain injury. J Cardiovasc Pharmacol 1995; 26 (3 Suppl.): S404–7

    Google Scholar 

  95. 95.

    Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283 (3): 1110–8

    PubMed  CAS  Google Scholar 

  96. 96.

    Dawson DA, Hallenbeck JM, Spatz M. The endothelin antagonist Ro 61-1790 attenuates focal cerebral ischaemic injury. Stroke 1998; 29: 323

    Article  Google Scholar 

  97. 97.

    Frasch HF, Marshall C, Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999; 276 (2 Pt 1): L304–10

    PubMed  CAS  Google Scholar 

  98. 98.

    Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin- 1 in pulmonary hypertension: marker or mediator of disease? Ann Int Med 1991; 114: 464–9

    PubMed  CAS  Google Scholar 

  99. 99.

    Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin- 1 in lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328 (24): 1732–9

    PubMed  Article  CAS  Google Scholar 

  100. 100.

    Franco-Cereceda A, Holm P. Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension. J Cardiovasc Pharmacol 1998; 31 Suppl. 1: S447–52

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to David J. Webb.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Goddard, J., Webb, D.J. Endothelin Receptor Antagonists. Drugs R&D 2, 1–12 (1999). https://doi.org/10.2165/00126839-199902010-00001

Download citation

Keywords

  • Adis International Limited
  • Bosentan
  • Selective Receptor Antagonist
  • Nonselective Receptor